Joyson Poulose, MD
Guthrie Provider
- Hematology
- Medical Oncology
- Guthrie Robert Packer Hospital
Appointments & Contact
Accepting New Patients
Offers Telemedicine Visits
Information Icon
Telemedicine video visits make it easier to find care at a time and location that is convenient for you. Telemedicine appointments are available for both new patient visits and follow-ups.
For New Patients
Locations
-
Also Offers Telemedicine Information Icon866-488-4743Telemedicine video visits make it easier to find care at a time and location that is convenient for you. Telemedicine appointments are available for both new patient visits and follow-ups.
Education
- UPMC Pinnacle, Harrisburg, Pa. (Internal Medicine)
- American Society of Clinical Oncology
- American Society of Hematology
- American Board of Internal Medicine
- Saint James School of Medicine, Bonaire, Netherlands-Antilles
- Pennsylvania State University Milton S. Hershey Medical Center, Hershey, Pa. (Hematology/Oncology)
News & Video
Clinical Trials
- A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T
- A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
- A021703: Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
- A031704: PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]
- A031902 CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer
- A171901: OLDER NON-SMALL CELL LUNG CANCER PATIENTS (>/= 70 YEARS OF AGE) TREATED WITH FIRST-LINE MK-3475 (PEMBROLIZUMAB) +/- CHEMOTHERAPY (ONCOLOGIST'S/PATIENT'S CHOICE)
- Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
- ARC-7, Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
- BNT111-01: Open-label, Randomized Phase II Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD1-refractory/Relapsed, Unresectable Stage III or IV Melanoma
- E4512, A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
- EA5181: Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
- EA5191: A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC.
- FRNM-008 The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
- ICP-CL-00107: A Phase I/II Multicenter, Open-Label, Study of a Novel Bruton's Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients with B-Cell Malignancies
- Isolation of Oxaliplatin-Resistant Circulating Tumor Cells from Colorectal Cancer Patient Blood
- LungMap (Screening Protocol for Lung-Map):
- NRG-LU005: Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
- NRG-LU007: Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
- S1501, Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
- S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Patient Comments